Etoposide as a single agent in the treatment of mycosis fungoides

A retrospective analysis

Seda Purnak, Jose Azar, Lawrence Mark

Research output: Contribution to journalArticle

Abstract

Several chemotherapy agents have shown efficacy in the treatment of mycosis fungoides (MF). In the literature, there is limited data on the use of single agent etoposide for MF. We aimed to retrospectively review our experience with single agent etoposide in the treatment of advanced-stage or refractory early-stage MF with focus on analyzing its efficacy and safety. We included 13 MF patients who were treated with single agent etoposide. Patients were identified through the Cutaneous T Cell Lymphoma Database of Indiana University that involves patients treated from 2006 to 2016. Overall nine patients (69%) responded to treatment. No complete response was identified. Median time to response was 12.5 weeks (range: 6–25.4). Median duration of response was 43 weeks (range: 5–60) and median time to treatment failure was 31.3 weeks (range: 12.4–230). Hematological toxicity was observed in eight patients including two patients with grade 4 neutropenia and/or lymphopenia leading to sepsis. Higher doses of etoposide were significantly correlated with higher grades of anemia, neutropenia or lymphopenia (p <.05). Our study demonstrates that etoposide is an effective treatment for MF and may be considered in selected patients with progressive MF who have failed other treatments.

Original languageEnglish (US)
Article numbere12586
JournalDermatologic Therapy
Volume31
Issue number2
DOIs
StatePublished - Mar 1 2018

Fingerprint

Mycosis Fungoides
Etoposide
Lymphopenia
Neutropenia
Therapeutics
Cutaneous T-Cell Lymphoma
Treatment Failure
Anemia
Sepsis
Databases
Safety
Drug Therapy

Keywords

  • chemotherapy
  • cutaneous T-cell lymphoma
  • etoposide
  • mycosis fungoides

ASJC Scopus subject areas

  • Dermatology

Cite this

Etoposide as a single agent in the treatment of mycosis fungoides : A retrospective analysis. / Purnak, Seda; Azar, Jose; Mark, Lawrence.

In: Dermatologic Therapy, Vol. 31, No. 2, e12586, 01.03.2018.

Research output: Contribution to journalArticle

@article{cd415c389fb84c80b26ad87e927e6aa0,
title = "Etoposide as a single agent in the treatment of mycosis fungoides: A retrospective analysis",
abstract = "Several chemotherapy agents have shown efficacy in the treatment of mycosis fungoides (MF). In the literature, there is limited data on the use of single agent etoposide for MF. We aimed to retrospectively review our experience with single agent etoposide in the treatment of advanced-stage or refractory early-stage MF with focus on analyzing its efficacy and safety. We included 13 MF patients who were treated with single agent etoposide. Patients were identified through the Cutaneous T Cell Lymphoma Database of Indiana University that involves patients treated from 2006 to 2016. Overall nine patients (69{\%}) responded to treatment. No complete response was identified. Median time to response was 12.5 weeks (range: 6–25.4). Median duration of response was 43 weeks (range: 5–60) and median time to treatment failure was 31.3 weeks (range: 12.4–230). Hematological toxicity was observed in eight patients including two patients with grade 4 neutropenia and/or lymphopenia leading to sepsis. Higher doses of etoposide were significantly correlated with higher grades of anemia, neutropenia or lymphopenia (p <.05). Our study demonstrates that etoposide is an effective treatment for MF and may be considered in selected patients with progressive MF who have failed other treatments.",
keywords = "chemotherapy, cutaneous T-cell lymphoma, etoposide, mycosis fungoides",
author = "Seda Purnak and Jose Azar and Lawrence Mark",
year = "2018",
month = "3",
day = "1",
doi = "10.1111/dth.12586",
language = "English (US)",
volume = "31",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Etoposide as a single agent in the treatment of mycosis fungoides

T2 - A retrospective analysis

AU - Purnak, Seda

AU - Azar, Jose

AU - Mark, Lawrence

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Several chemotherapy agents have shown efficacy in the treatment of mycosis fungoides (MF). In the literature, there is limited data on the use of single agent etoposide for MF. We aimed to retrospectively review our experience with single agent etoposide in the treatment of advanced-stage or refractory early-stage MF with focus on analyzing its efficacy and safety. We included 13 MF patients who were treated with single agent etoposide. Patients were identified through the Cutaneous T Cell Lymphoma Database of Indiana University that involves patients treated from 2006 to 2016. Overall nine patients (69%) responded to treatment. No complete response was identified. Median time to response was 12.5 weeks (range: 6–25.4). Median duration of response was 43 weeks (range: 5–60) and median time to treatment failure was 31.3 weeks (range: 12.4–230). Hematological toxicity was observed in eight patients including two patients with grade 4 neutropenia and/or lymphopenia leading to sepsis. Higher doses of etoposide were significantly correlated with higher grades of anemia, neutropenia or lymphopenia (p <.05). Our study demonstrates that etoposide is an effective treatment for MF and may be considered in selected patients with progressive MF who have failed other treatments.

AB - Several chemotherapy agents have shown efficacy in the treatment of mycosis fungoides (MF). In the literature, there is limited data on the use of single agent etoposide for MF. We aimed to retrospectively review our experience with single agent etoposide in the treatment of advanced-stage or refractory early-stage MF with focus on analyzing its efficacy and safety. We included 13 MF patients who were treated with single agent etoposide. Patients were identified through the Cutaneous T Cell Lymphoma Database of Indiana University that involves patients treated from 2006 to 2016. Overall nine patients (69%) responded to treatment. No complete response was identified. Median time to response was 12.5 weeks (range: 6–25.4). Median duration of response was 43 weeks (range: 5–60) and median time to treatment failure was 31.3 weeks (range: 12.4–230). Hematological toxicity was observed in eight patients including two patients with grade 4 neutropenia and/or lymphopenia leading to sepsis. Higher doses of etoposide were significantly correlated with higher grades of anemia, neutropenia or lymphopenia (p <.05). Our study demonstrates that etoposide is an effective treatment for MF and may be considered in selected patients with progressive MF who have failed other treatments.

KW - chemotherapy

KW - cutaneous T-cell lymphoma

KW - etoposide

KW - mycosis fungoides

UR - http://www.scopus.com/inward/record.url?scp=85044715017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044715017&partnerID=8YFLogxK

U2 - 10.1111/dth.12586

DO - 10.1111/dth.12586

M3 - Article

VL - 31

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

IS - 2

M1 - e12586

ER -